Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | +4.48% | -6.44% | +36.17% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.17% | 82.56M | |
+8.71% | 114B | |
+11.27% | 104B | |
-12.73% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.07% | 17.89B | |
+8.01% | 14.28B | |
+35.27% | 12.55B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Transcript : Passage Bio, Inc. Presents at Goldman Sachs 42nd Annual Global Healthcare Conference, Jun-10-2021 11